Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic “Overlap” severe asthma: Biological agent preference in atopic-eosinophilic severe asthma

Approximately 1-third of patients with severe asthma are candidates for both omalizumab and mepolizumab treatment. We aimed to compare the clinical, spirometric and inflammatory efficacy of these 2 biologics in atopic and eosinophilic “overlap” severe asthma patients. In our 3-center retrospective c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tepetam, Fatma Merve, Akyildiz, Ali Burkan, Özden, Şeyma, Örcen, Cihan, Yakut, Tuğçe, Atik, Özge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
6700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158900/
https://www.ncbi.nlm.nih.gov/pubmed/37144999
http://dx.doi.org/10.1097/MD.0000000000033660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158900/
https://www.ncbi.nlm.nih.gov/pubmed/37144999
http://dx.doi.org/10.1097/MD.0000000000033660

Ejemplares similares